|
KMID : 0370220180620040213
|
|
Yakhak Hoeji
2018 Volume.62 No. 4 p.213 ~ p.225
|
|
|
A Review of Efficacy and Safety of Tenofovir and/or Emtricitabine for HIV Pre-exposure Prophylaxis based on Clinical Trials
|
|
Yang Young-Mo
Choi Eun-Joo
|
|
|
Abstract
|
|
|
|
Oral tenofovir disoproxil fumarate (TDF) with or without emtricitabine (FTC) for preexposure prophylaxis(PrEP) against HIV infection in HIV-negative individuals can decrease the opportunities of HIV transmission. The currentreview aimed to assess efficacy and safety of TDF and FTC for PrEP against HIV infection and to provide clinical perspectiveson TDF and FTC for PrEP. A literature search of clinical studies published in PubMed and posted on ClinicalTrials. gov website was carried out to identify studies assessing the efficacy and safety of TDF and FTC for HIV PrEP. Seventeen studies were examined in this review. TDF and TDF/FTC for HIV PrEP generally showed effectiveness comparedwith placebo. Irrespective of the primary HIV transmission routes, PrEP was highly effective when used; however,PrEP for vaginal exposure was not significantly protective against HIV transmission. The safety profile of PrEP was comparablewith that of placebo, but adverse events related with renal function and bone mineral density (BMD) seemed to takeplace more frequently among those who received PrEP compared with placebo. The data presented in this review suggestthat PrEP in HIV-uninfected individuals could be effective for the prevention of HIV acquisition. PrEP could have negativeeffects on renal function and BMD.
|
|
|
KEYWORD
|
|
|
human immunodeficiency virus, preexposure prophylaxis, efficacy, safety, tenofovir, emtricitabine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|